| 1 |
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
Chunyan Wang, Rien van Haperen, Francisco J. Gutierrez-Alvarez et al. · Nature Communications
Open access |
17 Mar 2021 |
212 |
| 2 |
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Juliann Chmielecki, Tony S.K. Mok, Yi-Long Lung Cancer Wu et al. · Nature Communications
Open access |
27 Feb 2023 |
197 |
| 3 |
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
Bram Herpers et al. · Nature Cancer
Open access |
25 Apr 2022 |
171 |
| 4 |
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Alison M. Schram et al. · Cancer Discovery
Open access |
8 Feb 2022 |
171 |
| 5 |
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
Fathima Zumla Cader, Xihao Sherlock Hu, Walter L. Goh et al. · Nature Medicine
Open access |
10 Aug 2020 |
142 |
| 6 |
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Alison M. Schram et al. · New England Journal of Medicine
Open access |
5 Feb 2025 |
134 |
| 7 |
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Cecile A. W. Geuijen et al. · Nature Communications
Open access |
21 Jul 2021 |
116 |
| 8 |
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Cecile A. W. Geuijen, Camilla De Nardis, David Maussang et al. · Cancer Cell
Open access |
May 2018 |
110 |
| 9 |
Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells
Guoying Zhou, Ruby Lieshout, Gilles S. van Tienderen et al. · British Journal of Cancer
Open access |
21 May 2022 |
108 |
| 10 |
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1
Camilla De Nardis, Linda J. A. Hendriks, Emilie Poirier et al. · Journal of Biological Chemistry
Open access |
27 Jun 2017 |
104 |
| 11 |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2 -Amplified Gastrointestinal Carcinomas
Simonetta Maria Leto, Francesco Paolo Sassi, Irene Catalano et al. · Clinical Cancer Research
|
21 Aug 2015 |
104 |
| 12 |
The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers
Laura C. Zanetti-Domingues et al. · Nature Communications
Open access |
12 Oct 2018 |
99 |
| 13 |
Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform
Alex Klarenbeek, Khalil El Mazouari, Aline Desmyter et al. · mAbs
Open access |
27 May 2015 |
95 |
| 14 |
A Major Histocompatibility Complex·Peptide-restricted Antibody and T Cell Receptor Molecules Recognize Their Target by Distinct Binding Modes
Martin Hülsmeyer, Patrick Chames, Roman Christian Hillig et al. · Journal of Biological Chemistry
Open access |
10 Nov 2004 |
78 |
| 15 |
Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments
Gerhard Held, Mitsutoshi Matsuo, Malka Epel et al. · European Journal of Immunology
|
5 Aug 2004 |
71 |
| 16 |
Antibody cocktails: next-generation biopharmaceuticals with improved potency
Ton Logtenberg · Trends in biotechnology
Review |
8 Aug 2007 |
71 |
| 17 |
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis
Pieter Fokko van Loo, Basav N. Hangalapura, Soley Thordardottir et al. · Expert Opinion on Biological Therapy
Open access |
3 Jul 2019 |
63 |
| 18 |
Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
Tristan Gallenne, Kenneth N. Ross, Nils L. Visser et al. · Oncotarget
Open access |
15 Mar 2017 |
49 |
| 19 |
CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses
Tim J A Hutten, Soley Thordardottir, Hanny Fredrix et al. · The Journal of Immunology
|
27 Aug 2016 |
46 |
| 20 |
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
Dong‐Wan Kim, Alison M. Schram, Antoine Hollebecque et al. · Future Oncology
Open access |
13 Feb 2024 |
43 |
| 21 |
Qualitative and Semiquantitative Analysis of Composite Mixtures of Antibodies by Native Mass Spectrometry
Sara Rosati, Natalie Thompson, Arjan Barendregt et al. · Analytical Chemistry
|
10 Aug 2012 |
42 |
| 22 |
Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications
Renée C.G. de Bruin, Sinéad M. Lougheed, Liza van der Kruk et al. · Clinical Immunology
Open access |
2 Jul 2016 |
40 |
| 23 |
Generation of stable cell clones expressing mixtures of human antibodies
John de Kruif, Arjen Kramer, Roy Nijhuis et al. · Biotechnology and Bioengineering
|
16 Apr 2010 |
38 |
| 24 |
Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry
Natalie Thompson, Linda J. A. Hendriks, John de Kruif et al. · mAbs
Open access |
11 Nov 2013 |
37 |
| 25 |
Development of Plasmodium falciparum liver-stages in hepatocytes derived from human fetal liver organoid cultures
Annie Yang, Devanjali Dutta, Kai Kretzschmar et al. · Nature Communications
Open access |
2 Aug 2023 |
36 |
| 26 |
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker et al. · Investigational New Drugs
Open access |
5 May 2018 |
34 |
| 27 |
Systematic study of tissue factor expression in solid tumors
Johann Sebastian De Bono, Jeffrey R. Harris, Saskia Maria Burm et al. · Cancer Reports
Open access |
13 Aug 2022 |
32 |
| 28 |
Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML
Pieter Fokko van Loo, Robert P. Doornbos, Harry Dolstra et al. · Blood
|
3 Dec 2015 |
32 |
| 29 |
Estimands for overall survival in clinical trials with treatment switching in oncology
Juliane Manitz, Natalia Kan‐Dobrosky, Hannes Buchner et al. · Pharmaceutical Statistics
|
3 Oct 2021 |
31 |
| 30 |
Estimand framework: Are we asking the right questions? A case study in the solid tumor setting
Michelle Casey, Evgeny Degtyarev, María José Lechuga et al. · Pharmaceutical Statistics
|
5 Nov 2020 |
25 |
| 31 |
Human Immunoglobulin Repertoires against Tetanus Toxoid Contain a Large and Diverse Fraction of High-Affinity Promiscuous VH Genes
John de Kruif, Arjen Kramer, Therèse Visser et al. · Journal of Molecular Biology
|
18 Feb 2009 |
24 |
| 32 |
Heparan sulfate proteoglycan expression in the regenerating zebrafish fin
Sebastian Keil, Mansi Gupta, Michael Brand et al. · Developmental Dynamics
Open access |
26 Feb 2021 |
22 |
| 33 |
Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects
José L. Jiménez, Viktoriya Stalbovskaya, Byron Jones · Pharmaceutical Statistics
Open access |
27 Dec 2018 |
22 |
| 34 |
PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation
Tiziana Adage, Francesca Del Bene, Francesco Fiorentini et al. · Cytokine
|
21 Aug 2015 |
22 |
| 35 |
Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical Applications
Ante S. Lundberg, Cecile A. W. Geuijen, Sally A. Hill et al. · Cancers
Open access |
14 May 2025 |
21 |
| 36 |
A Humanized Antibody against LRG1 that Inhibits Angiogenesis and Reduces Retinal Vascular Leakage
David M. Kallenberg, Vineeta Tripathi, Faiza Javaid et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
25 Jul 2020 |
21 |
| 37 |
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
Aurelia H. M. de Vries Schultink, Kees Bol, Robert P. Doornbos et al. · Clinical Pharmacokinetics
Open access |
31 Jan 2020 |
18 |
| 38 |
Selection and characterization of llama single domain antibodies against N-terminal huntingtin
Menno H. Schut, Barry A. Pepers, Rinse Klooster et al. · Neurological Sciences
Open access |
7 Oct 2014 |
18 |
| 39 |
An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model
Viki Bockstal, Machteld M. Tiemessen, Rogier Achterberg et al. · Vaccine
Open access |
9 Oct 2018 |
15 |
| 40 |
HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine design
Amy L. Kessler, Roel F. A. Pieterman, Wouter A. S. Doff et al. · npj Vaccines
Open access |
18 Jan 2025 |
14 |
| 41 |
1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Alison M. Schram, Teresa Mercade Macarulla, James M. Cleary et al. · Annals of Oncology
Open access |
Oct 2023 |
14 |
| 42 |
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC
Jean‐Pascal Machiels, Jérôme Fayette, Robert I. Haddad et al. · Future Oncology
Open access |
13 Jun 2025 |
12 |
| 43 |
411MO Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial
Christophe Le Tourneau, J. Fayette, CHRISTIAN EVEN et al. · Annals of Oncology
Open access |
Dec 2024 |
12 |
| 44 |
Phage display generation of a novel human anti‐ CD 1 A monoclonal antibody with potent cytolytic activity
Gitanjali I. Bechan, David W. Lee, Dirk M. Zajonc et al. · British Journal of Haematology
Open access |
30 Aug 2012 |
12 |
| 45 |
Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial
Sophia M. van der Hoeven, Jan M. Binnekade, Corianne A.J.M. de Borgie et al. · Trials
Open access |
Sep 2015 |
12 |
| 46 |
Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial
Bart Geboers, Florentine E. F. Timmer, Danielle J. W. Vos et al. · Journal for ImmunoTherapy of Cancer
Open access |
Mar 2025 |
11 |
| 47 |
1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Alison M. Schram, Kōichi Goto, Dongwook Kim et al. · Annals of Oncology
Open access |
Oct 2023 |
11 |
| 48 |
Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts
Hendrik J. Kuiken, Sabin Dhakal, Laura M. Selfors et al. · Oncogene
Open access |
26 Oct 2021 |
10 |
| 49 |
Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
María Alsina, Andréa Varga, Alessio Amatu et al. · Annals of Oncology
Open access |
Oct 2018 |
10 |
| 50 |
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor
Elisa Fontana, Gonzalo Torga, Raluca Maria Fostea et al. · JCO Precision Oncology
Open access |
Aug 2022 |
9 |